ArticleVaccine2008
Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge.Vaccines · 2025Article
- Early, adjuvant-responsive epigenetic programs in B cells imprint subsequent plasma cell survival and the duration of humoral immunity.bioRxiv : the preprint server for biology · 2025Article
- A fusion protein of vimentin with Fc fragment inhibits Japanese encephalitis virus replication.Frontiers in veterinary science · 2024Article
- Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus.Vaccines · 2023Article
- Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection.Frontiers in cellular and infection microbiology · 2023Article
- Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases.Viruses · 2022Review
- Article
- Plant-Produced Antigen Displaying Virus-Like Particles Evokes Potent Antibody Responses against West Nile Virus in Mice.Vaccines · 2021Article
- Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced inVaccines · 2020Review
- A Molecular Determinant of West Nile Virus Secretion and Morphology as a Target for Viral Attenuation.Journal of virology · 2020Article
- A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.NPJ vaccines · 2020Article
- Article
- West Nile virus vaccines - current situation and future directions.Human vaccines & immunotherapeutics · 2019Review
- An Evolutionary Insight into Zika Virus Strains Isolated in the Latin American Region.Viruses · 2018Article
- Article
- Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.Virology · 2016Article
- Article
- An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses.PloS one · 2015Article
- Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.Molecular biotechnology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Japanese encephalitis virus (JEV) serocomplex-group consists of mosquito-borne flaviviruses, which include West Nile virus (WNV) and JEV, and both may cause severe encephalitis in humans. WNV has spread rapidly across the United States since its introduction in 1999 and its geographical distribution within the western hemisphere is expected to further expand, whereas, JEV is the most common cause of viral encephalitis in Southeast Asia, China and India. Currently, there is no registered human vaccine or specific therapy to prevent or treat WNV infection. Here we describe the efficacy of recombinant domain III (DIII) of WNV glycoprotein E in a mouse model. It induces high neutralizing antibody titers, as well as, protection against lethal WNV infection in C57BL/6 mice. This vaccine preparation also afforded partial protection against lethal JEV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.